About LIQID Medical

LIQID Medical develops lifelong implants for glaucoma treatment that utilize the retrolaminar drainage pathway, providing a novel approach to managing this leading cause of irreversible blindness. Their QMAX and QFLOW devices aim to enhance surgical efficiency and patient outcomes by addressing the limitations of traditional drainage methods.

```xml <problem> Glaucoma, a leading cause of irreversible blindness, often requires surgical intervention when medication and laser treatments fail to adequately lower intraocular pressure (IOP). Traditional glaucoma drainage devices can suffer from complications related to the subconjunctival drainage pathway, such as bleb formation and subsequent failure. </problem> <solution> LIQID Medical is developing lifelong implants that utilize the retrolaminar drainage pathway to manage glaucoma. Their QMAX device is designed as a highly effective glaucoma solution that bypasses the traditional subconjunctival drainage pathway. The QFLOW device harnesses the traditional fluid drainage pathway, but with an innovative design intended to reduce surgical operating times, costs, and complications. Both devices aim to improve surgical efficiency and patient outcomes by providing effective, long-term IOP control. </solution> <features> - QMAX implant utilizes the retrolaminar drainage pathway, avoiding subconjunctival complications. - QFLOW implant employs an innovative design to optimize traditional fluid drainage. - Devices are intended to provide long-term IOP control, reducing the need for repeat surgeries. </features> <target_audience> The primary target audience includes glaucoma surgeons and patients with severe or refractory glaucoma requiring surgical intervention for IOP management. </target_audience> ```

What does LIQID Medical do?

Where is LIQID Medical located?

LIQID Medical is based in Cape Town, South Africa.

When was LIQID Medical founded?

LIQID Medical was founded in 2017.

How much funding has LIQID Medical raised?

LIQID Medical has raised 2240000.

Location

Cape Town, South Africa

Founded

2017

Funding

2240000

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

LIQID Medical

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

liqidmedical.com LinkedIn Profile

Founded 2017 – Cape Town, South Africa

Funding

Estimated Funding

$2M+

Team

No team information available.

Company Description

Problem

Glaucoma, a leading cause of irreversible blindness, often requires surgical intervention when medication and laser treatments fail to adequately lower intraocular pressure (IOP). Traditional glaucoma drainage devices can suffer from complications related to the subconjunctival drainage pathway, such as bleb formation and subsequent failure.

Solution

LIQID Medical is developing lifelong implants that utilize the retrolaminar drainage pathway to manage glaucoma. Their QMAX device is designed as a highly effective glaucoma solution that bypasses the traditional subconjunctival drainage pathway. The QFLOW device harnesses the traditional fluid drainage pathway, but with an innovative design intended to reduce surgical operating times, costs, and complications. Both devices aim to improve surgical efficiency and patient outcomes by providing effective, long-term IOP control.

Features

QMAX implant utilizes the retrolaminar drainage pathway, avoiding subconjunctival complications.

QFLOW implant employs an innovative design to optimize traditional fluid drainage.

Devices are intended to provide long-term IOP control, reducing the need for repeat surgeries.

Target Audience

The primary target audience includes glaucoma surgeons and patients with severe or refractory glaucoma requiring surgical intervention for IOP management.